STING1 and cancer: Type I IFNs have been linked with multiple positive effects on anti‐tumoral immune cells such as enhanced cytotoxicity of natural killer (NK) cells, increased intratumoral accumulation, differentiation, and activation of DCs and therefore elevated T cell responses and inducing higher apoptosis of tumor cells.[12] In this way, the STING pathway can not only kickstart but also act on later phases of the cancer immunity cycle.